GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PMV Pharmaceuticals Inc (NAS:PMVP) » Definitions » Net Debt Paydown Yield %

PMV Pharmaceuticals (PMV Pharmaceuticals) Net Debt Paydown Yield % : 0.14% (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PMV Pharmaceuticals Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, PMV Pharmaceuticals's Net Debt Paydown Yield % was 0.14%.


PMV Pharmaceuticals Net Debt Paydown Yield % Historical Data

The historical data trend for PMV Pharmaceuticals's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PMV Pharmaceuticals Net Debt Paydown Yield % Chart

PMV Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial - - - -1.02 -0.25

PMV Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.54 -0.40 -0.25 0.17

Competitive Comparison of PMV Pharmaceuticals's Net Debt Paydown Yield %

For the Biotechnology subindustry, PMV Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PMV Pharmaceuticals's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where PMV Pharmaceuticals's Net Debt Paydown Yield % falls into.



PMV Pharmaceuticals Net Debt Paydown Yield % Calculation

PMV Pharmaceuticals's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 13.14-13 )/87.45803
=0.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


PMV Pharmaceuticals  (NAS:PMVP) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


PMV Pharmaceuticals Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of PMV Pharmaceuticals's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


PMV Pharmaceuticals (PMV Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1 Research Way, Princeton, NJ, USA, 08536
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Leila Alland officer: Chief Medical Officer C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Deepika Jalota officer: SVP, Regulatory Affairs and QA C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Orbimed Capital Gp V Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Kirsten Flowers director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Thilo Schroeder director, 10 percent owner C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Arnold J Levine director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Winston Kung officer: COO, CFO C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
David Henry Mack director, officer: President and CEO ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Euclidean Capital Llc 10 percent owner 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010
James H Simons 10 percent owner RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022
Greenland A Llc 10 percent owner C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010

PMV Pharmaceuticals (PMV Pharmaceuticals) Headlines

From GuruFocus